InvestorsHub Logo

AMA

Followers 739
Posts 62865
Boards Moderated 1
Alias Born 12/05/2006

AMA

Re: MiamiGent post# 39451

Monday, 11/15/2021 6:05:59 PM

Monday, November 15, 2021 6:05:59 PM

Post# of 40501
From yahoo...From The Stifel Conference today. VGX 3100 Reveal 2 Going Well Meeting All Endpoints Plus They Discussed The Use Of QIAGEN Data. Women That Exhibit Certain Biomarkers Will Respond Well To The VGX 3100 Treatment. This Data Will Be Part Of INOVIO's Trial Submission For FDA Approval. BTW, with QIAGEN a 11 billion dollar company involved the efficacy will be magnified. Precise targeted medicine.....Dr. Jeffrey Skolnik M.D. Senior V.P. Clinical Development discussed INO 5401 and VGX 3100. Very excited about both!. Two year survival data for INO 5401/Libtayo is stellar way beyond the standard of care!. Regeneron will fast track this and they have the clout to get it done. Laurent Humeau Chief Scientific Officer discussed ramping up INO 4800 Covid 19 Vaccine and Cellectra Device production. Alluded to vaccine orders in the works with several countries. The WHO likes the data and stated INO 4800 is much superior to Zydus the Indian DNA vaccine. We can expect news any day INO 5401/Libtayo 2 year results from INOVIO and Regeneron. We are about to witness a move that few see in a lifetime.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent INO News